Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

Munshi, Pashna N. ; Hamadani, Mehdi ; Kumar, Ambuj ; Dreger, Peter ; Friedberg, Jonathan W. ; Dreyling, Martin ; Kahl, Brad ; Jerkeman, Mats LU ; Kharfan-Dabaja, Mohamed A. and Locke, Frederick L. , et al. (2021) In Bone Marrow Transplantation 56(12). p.2911-2921
Abstract

Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen receptor (CAR) T-cell therapy received approval for MCL; however, its exact place and sequence in relation to HCT is unclear. The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-HCT, and CAR T-cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated; in the first-line setting auto-HCT consolidation represents... (More)

Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen receptor (CAR) T-cell therapy received approval for MCL; however, its exact place and sequence in relation to HCT is unclear. The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-HCT, and CAR T-cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated; in the first-line setting auto-HCT consolidation represents standard-of-care in eligible patients, whereas there is no clear role of allo-HCT or CAR T-cell therapy, outside of a clinical trial. In the R/R setting, the preferential option is CAR T-cell therapy especially in MCL failing or intolerant to at least one Bruton’s tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T-cell therapy has failed or is not feasible. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Bone Marrow Transplantation
volume
56
issue
12
pages
2911 - 2921
publisher
Nature Publishing Group
external identifiers
  • pmid:34413469
  • scopus:85113212083
ISSN
0268-3369
DOI
10.1038/s41409-021-01288-9
language
English
LU publication?
yes
id
879ee387-cb8c-48f6-a573-622a1b2fc594
date added to LUP
2021-09-06 14:45:03
date last changed
2024-04-20 10:45:02
@article{879ee387-cb8c-48f6-a573-622a1b2fc594,
  abstract     = {{<p>Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen receptor (CAR) T-cell therapy received approval for MCL; however, its exact place and sequence in relation to HCT is unclear. The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-HCT, and CAR T-cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated; in the first-line setting auto-HCT consolidation represents standard-of-care in eligible patients, whereas there is no clear role of allo-HCT or CAR T-cell therapy, outside of a clinical trial. In the R/R setting, the preferential option is CAR T-cell therapy especially in MCL failing or intolerant to at least one Bruton’s tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T-cell therapy has failed or is not feasible. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.</p>}},
  author       = {{Munshi, Pashna N. and Hamadani, Mehdi and Kumar, Ambuj and Dreger, Peter and Friedberg, Jonathan W. and Dreyling, Martin and Kahl, Brad and Jerkeman, Mats and Kharfan-Dabaja, Mohamed A. and Locke, Frederick L. and Shadman, Mazyar and Hill, Brian T. and Ahmed, Sairah and Herrera, Alex F. and Sauter, Craig S. and Bachanova, Veronika and Ghosh, Nilanjan and Lunning, Matthew and Kenkre, Vaishalee P. and Aljurf, Mahmoud and Wang, Michael and Maddocks, Kami J. and Leonard, John P. and Kamdar, Manali and Phillips, Tycel and Cashen, Amanda F. and Inwards, David J. and Sureda, Anna and Cohen, Jonathon B. and Smith, Sonali M. and Carlo-Stella, Carmello and Savani, Bipin and Robinson, Stephen P. and Fenske, Timothy S.}},
  issn         = {{0268-3369}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{2911--2921}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Bone Marrow Transplantation}},
  title        = {{ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma}},
  url          = {{http://dx.doi.org/10.1038/s41409-021-01288-9}},
  doi          = {{10.1038/s41409-021-01288-9}},
  volume       = {{56}},
  year         = {{2021}},
}